Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial

Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol

“…In particular, the last 3 contraindications were introduced in 2013 by the European Medicines Agency (EMA) following a referral procedure 20 Interestingly in this study, cilostazol was started 6 months after revascularization (after discontinuation of thienopyridine), and it was found still effective in improving the primary end point. Prescribers also need to be aware of the risk of interactions with cilostazol: its dose should be reduced in patients concurrently taking strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, and erythromycin) or CYP2C19 enzymes (e.g., omeprazole; Table III).…”

“…A recent randomized study has also evaluated the effect of a cilostazol treatment started 6 months after a coronary stent implantation, following the withdrawal of one of the dual standard antiplatelet treatments, versus patients continuously treated with a single antiplatelet treatment after the drug withdrawal. Results show that the cilostazol treatment has efficiently and significantly reduced the incidence of the study primary end points (death combined score for any cause, myocardial infarction, stroke, and revascularization intervention) up to 2-year follow-up (À39%, P ¼ 0.021) 20 (Fig. 2).…”

“…36 In clinical trials, after a percutaneous coronary revascularization, the treatment was generally started the day after the intervention for a period of 12e24 months. Interestingly, the scheme of a recent study by Ueda et al 20 provided a cilostazol treatment starting from 6 months after revascularization in patients who had withdrawn from one of the standard dual antiplatelet treatments administered (Fig. 2).…”

Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study

“…Cilostazol, a selective inhibitor of cyclic nucleotide phosphodiesterase 3, has many pharmacological activities, including anti-inflammatory, antioxidative, and antiapoptotic effects in the brain [14]. It has been found to be beneficial in the treatment of ischemic heart disease and poststroke patients [15][16][17]. In addition, cilostazol has been found to prevent cerebral hypoperfusion-induced cognitive impairment and white matter damage induced by occluding the common carotid artery by bilateral ligation in rats [18].…”

Successful everolimus-eluting stent implantation into the left main trunk stenosis in the anomalous coronary artery after neo-aortic valve replacement in a 6-year-old boy

“…Dual antiplatelet therapy using aspirin and clopidogrel or cilostazol after drug-eluting stent deployment is not only a wellrecognized supportive care in adults but also effective in reducing the probability of thrombotic events and the restenosis rate in small children. 9 This patient had been taking warfarin and aspirin to prevent mechanical valve thrombosis. We added cilostazol to prevent restenosis, and follow-up angiography showed complete stent patency.…”